Scintomics and 1717 Life Science Ventures Team up in the Joint Venture PENTIXAPHARM to Develop CXCR4-Targeted Theranostics
Scintomics GmbH and 1717 Life Science Ventures GmbH announced today to have signed an agreement to collaborate in the development of the theranostic pair PentixaFor / PentixaTher.
PentixaPharm GmbH, based in Würzburg, is committed to develop PentixaFor and PentixaTher as a theranostic radiopharmaceutical pair, specifically targeting the CXCR4-receptor expressed in most fast progressing diseases, particularly malignant cancers.
Interviews: “We are delighted that in 1717 LSV we have found a strong partner with an outstanding expertise in the clinical development of precision oncologics. Taking the various recent and successful proof-of-concept studies with PentixaFor and PentixaTher in men into account, this joint venture creates optimal conditions for the effective and swift clinical development of this unrivalled and unique pair of theranostic drugs”, said Prof. Hans-Jürgen Wester, PhD, Founder of Scintomics and Chair for Pharmaceutical Radiochemistry at the Technical University of Munich (TUM), Germany.
“The introduction of 68 Ga-PentixaFor may be regarded as a milestone for clinical PET imaging of CXCR4 expressing malignancies”, added Dr. Hakim Bouterfa Co-founder of 1717 LSV GmbH and CEO of PentixaPharm. “Now we will focus on the next major step to provide CXCR4-directed endoradiotherapy in prospective clinical trials.”
About PentixaFor / PentixaTher
This theranostic pair specifically targets the CXCR4-CXCR12 axis, which is significantly involved in the interaction and proliferation of hematologic and solid tumors and their protective environment. The Gallium-68 based PET agent PentixaFor has demonstrated advanced imaging not only for several different hematologic indications – including leukaemia, lymphoma, and multiple myeloma – but also for other solid tumors like adrenocortical carcinoma, and small cell lung cancer. In addition, other disease conditions, such as atherosclerosis, myocardial infarction, splenosis and stroke and can be targeted with this tracer. The therapeutic counterpart PentixaTher, labeled with α- or β-emitters, offers new treatment options for individualised medicine in terms of endoradiotherapy.
About Scintomics GmbH
Scintomics, based in Fuerstenfeldbruck/Munich, is a privately held company for innovative-targeted theranostics and corresponding radiopharmaceutical technologies with a strong commitment towards personalized cancer care with an exceptional pipeline of functional diagnostics and radiotherapeutics. Scintomics considers the joint venture partnership with 1717 LSV as another important milestone towards a strong positioning as radiopharmaceutical development specialist.
About 1717 LSV GmbH
1717 LSV, based in Berlin, is a privately held company with expertise in the development of targeted precision radiopharmaceuticals for the targeted diagnosis and treatment of malignant oncological diseases. By enabling novel radiopharmaceutical therapies to traverse early stages of manufacturing and clinical development, 1717 LSV brings innovative drug candidates to patients with unmet medical needs.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190515005776/en/
Contact information
For Scintomics
Saskia Kropf
General Manager
tel.
+49 8141 150 550
s.kropf@scintomics.com
www.scintomics.com
For
1717 LSV
Dr. Jens Kaufmann
General Manager
tel. +49
30 941084-422
jens.kaufmann@1717LSV.com
www.1717LSV.com
For
PentixaPharm
Dr. Hakim Bouterfa
CEO
tel. +49 172
6290822 or +49 931 304998310
hakim.bouterfa@1717LSV.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Network Failures Cost $5M A Year for More Than a Quarter of Global Businesses, According to Expereo1.7.2025 11:00:00 EEST | Press release
Network instability is taking a serious toll on global businesses, with over a quarter (28%) reporting revenue losses of up to $5 million due to network outages or poor performance. Alarmingly, an additional 23% have experienced losses exceeding $5 million. These findings come from an IDC InfoBrief commissioned by Expereo, titled “Enterprise Horizons 2025: Technology Leaders Priorities: Achieving Digital Agility.” Following a series of high-profile IT disruptions over the past year, ranging from cybersecurity breaches to connectivity failures, nearly half (49%) of global businesses have been compelled to re-evaluate their technology infrastructure, and 40% of global tech leaders say it’s caused networking and connectivity to rise higher up the C-suite agenda. Perhaps as a result, networking/connectivity now comes out on top in terms of the technologies global businesses will prioritise in terms of financial investment over the next 12 months (43%). This is followed by Cybersecurity (38
Record Financing for NeXtWind: €1.4 Billion for the Expansion of Wind Energy in Germany1.7.2025 10:52:00 EEST | Press release
NeXtWind, a leading renewable energy company, has secured €1.4 billion in debt financing. The agreement also includes an additional €1.3 billion in so-called accordion facilities, which can be activated in tranches over the coming years. This syndicated loan is the largest of its kind for an independent wind energy provider in Germany, and it opens the onshore wind market to debt investments from major financial institutions both domestically and internationally. NeXtWind will use the new financing to modernize more than half of its wind farms, increasing their generation capacity to over 1 GW by 2028. Subsequently, the company plans to further develop these wind farms into sustainable energy infrastructure hubs. “This financing is a significant milestone for NeXtWind and testament to the confidence in our business model,” explains Lars B. Meyer, Co-CEO of NeXtWind. “Thanks to this novel platform approach, we can optimize our wind farms more quickly and accelerate our growth. In the lo
Celero Ventures Opens $25 Million Early-Stage Fund to Investors Backing the Next Generation of European Software Companies1.7.2025 10:30:00 EEST | Press release
Celero Ventures, a new venture capital firm founded by experienced software operators Dave Wyatt and Nick Cochran, is now raising its debut $25 million fund to invest in early-stage startups across the UK and Europe. The fund, which is already 25% subscribed, targets pre-seed and seed-stage companies building next-generation AI and data infrastructure. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250701820933/en/ Nick Cochran and David Wyatt (right) Founders of Celero Ventures Based in London, Celero Ventures is inviting limited partners (LPs) to join its mission of backing exceptional technical founders and accelerating their path to product-market fit and scalable growth. Wyatt and Cochran bring a rare combination of deep go-to-market (GTM) experience and startup leadership. Together, they helped scale both MuleSoft and Databricks—two of the most successful enterprise software companies of the past decade. Their experien
Cargill Sets a New Global Benchmark for More Sustainable Cocoa Supply Chains1.7.2025 10:00:00 EEST | Press release
Cargill today announced a transformation of its global cocoa supply chain, unveiling a series of interconnected investments that reduce carbon emissions, eliminate waste, and boost efficiency from cocoa origin countries in West Africa to processing hubs in Europe. The company’s upgrades span renewable energy, circular logistics, and smart infrastructure. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250701468198/en/ Cargill today announced a transformation of its global cocoa supply chain, unveiling a series of interconnected investments that reduce carbon emissions, eliminate waste, and boost efficiency from cocoa origin countries in West Africa to processing hubs in Europe. “Sustainability isn’t a single project at Cargill—it’s how we operate,” said Emiel van Dijk, Managing Director of Cocoa & Chocolate Europe and West Africa. “From circular waste reuse to renewable transport and clean energy, we’re showing that climate a
Lyten Acquires Europe’s Largest Battery Energy Storage Systems Manufacturing Operation from Northvolt1.7.2025 10:00:00 EEST | Press release
Lyten, the supermaterial applications company and global leader in lithium-sulfur batteries, announced today the acquisition of Northvolt’s Dwa ESS operations in Gdansk, Poland, a 25,000 square meter (270,000 sq ft) battery energy storage systems (BESS) manufacturing and R&D facility. Northvolt Dwa ESS is the largest BESS manufacturing facility in Europe and was part of Northvolt Systems. The financial terms of the acquisition are not being released by either party. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250701098618/en/ Aerial view of the 25,000-square meter battery energy storage systems manufacturing facility, in Gdansk, Poland, acquired by Lyten from Northvolt. The facility, previously known as Northvolt Dwa ESS, is Europe’s largest energy storage systems manufacturing operation. The Northvolt acquisition accelerates expansion of Lyten’s lithium-sulfur batteries into Europe and provides Lyten with production capa
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom